CTICUnknown
CTI BIOPHARMA CORP Insider Trading Activity
Every SEC Form 4 insider transaction reported for CTI BIOPHARMA CORP (CTIC), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are CTIC insiders buying or selling?
CTI BIOPHARMA CORP insiders reported 3 open-market buys ($5.0M) and 18 sells ($67.7M) across 21 Form 4 filings — a net selling position of $62.6M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jan 26, 2023)
Total Form 4 filings
21
SEC EDGAR
Insider filers
6
Insider buys (3)
$5.0M
Insider sells (18)
$67.7M
Insider sentiment
Net sellingNet insider flow of $62.6M in net selling.
Recent CTIC insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 26, 2023 | Adam R Craig | President and CEO | Sale | 85.3K | $6.00 | $511.9K |
| Jan 26, 2023 | James K Fong | EVP & Chief Commercial Officer | Sale | 100.0K | $6.00 | $600.0K |
| Jan 4, 2023 | Adam R Craig | President and CEO | Sale | 115.6K | $6.01 | $694.7K |
| Jan 3, 2023 | David Kirske | EVP, Chief Financial Officer | Sale | 54.0K | $6.01 | $324.6K |
| Nov 14, 2022 | Adam R Craig | President and CEO | Sale | 242.3K | $6.00 | $1.5M |
| Nov 10, 2022 | Michael A Metzger | Director | Sale | 91.5K | $5.58 | $511.0K |
| Oct 6, 2022 | David Kirske | EVP, Chief Financial Officer | Sale | 2.1K | $6.26 | $13.2K |
| Oct 3, 2022 | David Kirske | EVP, Chief Financial Officer | Sale | 141.0K | $6.05 | $852.8K |
| Sep 20, 2022 | David Kirske | EVP, Chief Financial Officer | Sale | 22.6K | $6.02 | $136.0K |
| Sep 14, 2022 | Adam R Craig | President and CEO | Sale | 242.3K | $6.43 | $1.6M |
| Aug 16, 2022 | Adam R Craig | President and CEO | Purchase | 5.0K | $5.50 | $27.5K |
| Aug 11, 2022 | Mark N Lampert | Director, 10% Owner | Sale | 8.5M | $6.12 | $52.0M |
| Jul 11, 2022 | Michael A Metzger | Director | Sale | 20.1K | $6.51 | $131.0K |
| Jul 7, 2022 | Michael A Metzger | Director | Sale | 91.5K | $6.08 | $556.1K |
| Jul 6, 2022 | Adam R Craig | President and CEO | Sale | 72.2K | $6.03 | $435.3K |
| Jun 17, 2022 | David Kirske | EVP, Chief Financial Officer | Sale | 60.0K | $6.21 | $372.5K |
| Jun 16, 2022 | David Kirske | EVP, Chief Financial Officer | Sale | 10.0K | $5.50 | $55.0K |
| Jun 3, 2022 | Adam R Craig | President and CEO | Sale | 72.2K | $6.00 | $433.5K |
| Dec 2, 2021 | Adam R Craig | President and CEO | Purchase | 3.5K | $1.52 | $5.3K |
| Apr 6, 2021 | Mark N Lampert | Director, 10% Owner | Purchase | 2.0M | $2.50 | $5.0M |
| Jan 11, 2021 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 2.0M | $3.50 | $7.0M |
Showing the 21 most recent of 21 Form 4 filings for CTI BIOPHARMA CORP.
Most active CTIC insiders
- Adam R Craig8 filings
- David Kirske6 filings
- Michael A Metzger3 filings
- Mark N Lampert2 filings
- James K Fong1 filing
Ask anything about CTIC insider activity
Use Trabud's AI agent to query CTI BIOPHARMA CORP's Form 4 history in plain English — "Show me CTIC CEO purchases this year" or compare it against any other ticker.
Open the AI agentCTIC insider trading FAQ
Are CTI BIOPHARMA CORP insiders buying or selling?
Across 21 SEC Form 4 filings, CTI BIOPHARMA CORP (CTIC) insiders reported 3 open-market purchases totaling $5.0M and 18 sales totaling $67.7M. That is a net selling position of $62.6M.
How many insiders trade CTIC stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for CTI BIOPHARMA CORP. The most recent filing was accepted on Jan 26, 2023.
Where does Trabud get CTIC insider trading data?
All CTIC insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.